

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yidu Tech Inc.
醫渡科技有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 2158)

ANNUAL RESULTS ANNOUNCEMENT FOR THE FISCAL YEAR ENDED 31 MARCH 2023

The board (the “**Board**”) of directors (the “**Directors**”) of Yidu Tech Inc. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) is pleased to announce the annual results of the Group for the fiscal year ended 31 March 2023 (the “**Reporting Period**”), together with the comparative figures for the fiscal year ended 31 March 2022. The results have been reviewed by the Company’s audit committee (the “**Audit Committee**”).

In this announcement, “we”, “us”, and “our” refer to the Company and where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

	Years ended 31 March		
	2023	2022	Change (%)
	<i>(RMB’000, except percentages)</i>		
Revenue	804,700	1,237,200	(35.0%)
— Big Data Platform and Solutions	221,863	444,891	(50.1%)
— Life Sciences Solutions	252,884	359,375	(29.6%)
— Health Management Platform and Solutions	329,953	424,941	(22.4%)
— Others	—	7,993	(100%)
Gross profit	274,530	399,445	(31.3%)
Operating loss	(630,049)	(767,398)	(17.9%)
Loss for the year	(632,361)	(766,360)	(17.5%)
Non-IFRS adjusted net loss ⁽¹⁾	(448,712)	(576,963)	(22.2%)

(1) We define “adjusted net loss” as loss for the year and adding back (i) share-based compensation expenses, and (ii) net foreign exchange losses.

The Board did not recommend the distribution of a final dividend for the fiscal year ended 31 March 2023.

BUSINESS REVIEW

In 2022, the global economic recovery faced multiple uncertainties due to complex and ever-changing unforeseen risks and challenges. The Group's operations also faced challenges due to the prolonged impact of the COVID-19 pandemic. Despite external pressures, we have maintained our focus on scenario-driven strategy and our dedication to technological innovation and disease research, which allowed us to achieve certain results in the development of artificial intelligence (“AI”) research and application solutions, expansion in the field of diseases, product upgrade and iteration, and market expansion.

The nation proposes to promote the construction of the “Healthy China”, putting the protection of people's health in a strategic position for prioritized development and improving the policy on the promotion of people's health. In 2022, the relevant national authorities have issued a series of policies and regulations that focus on promoting the construction of health informatization for the general public, high-quality development of public hospitals, the healthcare application scenarios empowered by AI, innovation in the healthcare supply side system, and refined operation and performance assessment of hospitals. Such market-friendly policies and better regulated market conditions enable us to deepen the development of our core technologies and capabilities, and achieve our vision of achieving precision healthcare for all (“**green healthcare**”) in the long run.

As a leading company in the healthcare intelligence industry, we are at the forefront in terms of applying AI and big data technologies to empower the transformation and upgrading of the healthcare industry along the supply chain for higher efficiency and meeting the diverse needs of the demand side of the healthcare ecosystem.

Our intelligent “medical brain”, YiduCore, empowers our customers and partners to unlock the value of data by enabling the secured applicability of high-quality data in different use-case scenarios. As of 31 March 2023, upon authorization, YiduCore has processed and analyzed more than 3.4 billion healthcare records from over 800 million patients. We focus on public health, research, and diagnosis and treatment scenarios, specializing in the disease areas of solid tumors, hematology, ophthalmology, immunology and cardiovascular. As algorithms and insightful medical knowledge continue to accumulate and iterate across different application scenarios and disease areas, we have attracted more hospitals, top-tier principal investigators, pharmaceutical companies and researchers to join the YiduCore network. As of 31 March 2023, we have provided solutions for 88 top research hospitals in China and 34 regulators and policymakers. The number of life science customers we have served reached 167. The number of active users who completed at least one transaction on our health management platform reached 20 million.

For the fiscal year ended 31 March 2023, our total revenue amounted to RMB804.7 million, representing a year-on-year decrease of 35.0%, mainly attributable to the prolonged pandemic, that resulted in the delays in bidding, on-site implementation and client acceptance of certain projects. Benefiting from improved internal operating efficiencies and enhanced synergies among our business segments, our loss for the year decreased to RMB632.4 million, representing a year-on-year decrease of 17.5%, and the adjusted net loss decreased to RMB448.7 million, representing a year-on-year decrease of 22.2%. Our net cash outflow for operating activities decreased by 41.9% on a year-on-year basis.

YiduCore

YiduCore, our intelligent “medical brain”, can be understood in terms of three layers: the first layer consists of our medical data governance capabilities, which enable us to assist in aggregating and converting raw and scattered data from in-hospital and out-of-hospital information technology systems into structured and standardised high-quality data that can be analysed and processed by algorithmic models in a rapid, accurate and cost-efficient manner upon authorization. The second layer is composed of our continuously reinforced and expanded medical knowledge, insights, and disease models generated from and applied in the intelligent algorithms, as they are applied to our data-analytics driven solutions for our customers in various use-case scenarios. The final layer is our scenario-specific operations and service capabilities that we develop to help our customers better realize the value of our solutions and ecosystem to achieve their target outcomes.

Since our incorporation, we have committed to research and independent innovation. We have continuously invested resources to deepen our understanding of diseases. The medical knowledge graphs in YiduCore are based on evidence-based medical research. As of 31 March 2023, the YiduCore medical knowledge graphs have covered over 90,000 medical subjects, of which the number of diseases covered by the disease knowledge graphs have exceeded 10,000, which supported the mapping of nearly 10 types of medical standard terminologies, such as ICD, MeSH and ATC etc. The continuously growing customer base can drive multi-scenario applications, and the iterative integration of scenarios and algorithms has further reinforced our YiduCore. As of 31 March 2023, YiduCore has built disease models in over 70 disease areas. In terms of medical natural language processing, as of 31 March 2023, upon authorization, YiduCore has processed and analyzed more than 3.4 billion healthcare records from over 800 million patients, covering over 1,500 hospitals. Through such accumulation, YiduCore is able to accurately identify over 15,000 medical semantic fields with industry-leading accuracy in medical text field extraction.

Based on the intelligent “medical brain”, YiduCore, we constantly improved the efficiency of research-grade evidence generation and deepened our research capability in different disease areas. In addition to the research on key diseases such as solid tumors, hematology, ophthalmology, immunology and cardiovascular, we further deepened our research on other diseases. During the Reporting Period, we supported the release of the China’s first cirrhosis standard dataset from technical perspective, to improve the data quality in utilization and integration of cirrhosis clinical resources. As of 31 March 2023, we have collaborated with experts and authoritative institutions to publish 15 disease standard datasets, building as a foundation for multi-center research in relevant disease areas. During the Reporting Period, we provided comprehensive scientific research service solutions to a Grade III-A hospital in East China, which ranks among the top two in thoracic surgery and tuberculosis in China. Our solutions enable full-process scientific research management, including CRF (Case Report Form) design, intelligent follow-up, and data quality control, thereby improving scientific research efficiency. Our comprehensive public health solutions provide large-scale simulation and prediction for efficient and dynamic decision-making. Our epidemic prediction and simulation products have been standardized and can be deployed remotely online with one click. As of 31 March 2023, the effectiveness and accuracy of our pandemic response and prediction algorithms have been validated in 23 provinces and cities.

Independent innovation and security protection are essential to YiduCore. Relying on YiduCore, the Medical Data Intelligent Platform Core Module (Version 2.7.0) (醫學數據智能平台核心模塊(2.7.0版本)) and Special Disease Intelligent Scientific Research Platform Core Module (Version 8.0.0) (專病智能科研平台核心模塊(8.0.0版本)), independently developed by us, have passed the evaluation of China Information Technology Security Evaluation Center and obtained the self-developed product evaluation certificate. We became the first healthcare technology company to obtain this certification. During the Reporting Period, with our excellent AI technology capabilities, we won the first prize at the “First Beijing Medical and Health Data Innovation and Application Competition (首屆北京醫療健康數據創新應用競賽)”, which was guided by Beijing Municipal Bureau of Economy and Information Technology, Beijing Municipal Health Commission and other authorities, and jointly hosted by Beijing International Data Exchange, Beijing Big Data Center (北京市大數據中心), Peking University People’s Hospital, Beijing Friendship Hospital, Beijing Chaoyang Hospital (北京朝陽醫院) and Beijing Chest Hospital (北京胸科醫院). With our leading scientific and technological innovation strength and intellectual property management capabilities, we were successfully accredited as the “National Intellectual Property Advantage Enterprise” in 2022, which is another state-class honor we have obtained after the “China Patent Award”.

For security protection, we have obtained the “Secure Multi-party Computing Basic Capability Special Evaluation Certificate (多方安全計算基礎能力專項評測證書)” and “Federated Learning Basic Capability Special Evaluation Certificate (聯邦學習基礎能力專項評測證書)” issued by China Academy of Information and Communications Technology. During the Reporting Period, we have participated in the preparation of the Research Report on the Application of Privacy Computing (2022) (《隱私計算應用研究報告(2022年)》) issued by the Institute of Cloud Computing and Big Data of the China Academy of Information and Communication Technology, which promoted the development and standardization of privacy computing and other relevant technical specifications. We will continue to improve the security protection capabilities of YiduCore and jointly promote the improvement of data security capabilities of the healthcare industry.

Big Data Platform and Solutions (“BDPS”)

In the BDPS segment, we provide data intelligence platform and data analytics-driven solutions for hospitals, other healthcare institutions, regulators and policymakers. During the Reporting Period, the revenue of this segment was RMB221.9 million, representing a decrease of 50.1% from the financial year ended 31 March 2022, mainly due to certain delays in tendering, on-site implementation and customer acceptance of certain projects arising from the prolonged impact of the COVID-19 pandemic. As of 31 March 2023, the number of top research hospital clients increased by 6 from FY2022 to 88, while the number of regulator and policymaker clients increased by 8 to 34.

For hospitals, we offer applications and solutions focused on three use-case scenarios, namely research, clinical diagnosis and treatment, and hospital operations management. The data analytics-driven applications and solutions we provided could further unlock the value of healthcare data to help clients conduct in-depth medical research and make precise and efficient decisions. By using our disease registries and disease research networks, top hospitals and experts can accelerate the production of research-grade evidence and scale up their clinical research in a faster and safer manner.

During the Reporting Period, we launched our new hospital scenario intelligent solutions, which will further broaden our target customer base with our All Disease Data Platform that enables the DIY creation of disease registries by hospitals. In addition, we also launched YiduEywa2.0, a new-generation data centre that serves as an open system platform covering clinical diagnosis, hospital management and research scenarios. This platform aims to help hospitals capitalize their medical data assets, accelerating the generation and transformation of research results. It enables the digitalization and intelligent transformation and upgrading of the entire hospital.

During the Reporting Period, we have supported the high-quality development and digital transformation of a number of top Grade III-A hospitals, including Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, and won the bid for a multi-center clinical research support platform construction project for a Grade III-A hospital in central China, with a contract value of over RMB10 million. Relying on the construction of the hospital's national medical centre project, we supported the hospital in building large clinical research cohorts and conducting large-sample multi-center cohort studies to improve research efficiency, and provided quality services for the hospital's multi-center research using advanced technologies such as artificial intelligence and algorithms.

We keep iterating real-world disease models by AI technologies, and continue to deepen our disease insights and engage top-grade hospitals and experts in our research network. In terms of ophthalmic diseases, we undertook the construction of ophthalmic disease registry of a Grade III-A hospital in Southwest China to continuously deepen our research on ophthalmic diseases. In addition, the “Tianjin Clinical Medical Research Centre for Eye Diseases Big Data Platform” that we have undertaken and provided technical support for, was officially launched. The platform is jointly developed by Tianjin Medical University Eye Hospital as the main center and collaborative institutions. It aims to integrate clinical, research and biological information system data in relation with eye diseases in Tianjin, covering intelligent patient recruitment, clinical operations, real-world studies, health economics research and other services. In addition to deepening our research on advantageous disease areas, we have also continuously expanded the breadth of our research in different disease areas. During the Reporting Period, we secured numerous disease registries projects in Grade III-A/Grade III hospitals, further strengthening our research capabilities in neurological diseases, orthopaedics and other disease areas.

We processed and analyzed more abundant and diverse data for regulators and policymakers. Upon authorization, we provide AI-enabled data analytics-driven solutions to regulators and policymakers, covering national/provincial/city-level regional platform development, public health, population health management, etc. To further promote the application and innovative development of new generation information technology in the healthcare industry, during the Reporting Period, the General Office of the National Health Commission released the list of the second batch of typical digital health cases. A total of 100 typical cases and 10 replicable demonstration cases were selected and commended in the notification. Among them, the “Wuhan Municipal Health Commission: Wuhan Public Health Emergency Command System” that we participated in its construction, was named as a replicable digital health demonstration case in the “Development of Big Data Applications in Health Care”. “The Hospital of Blood Diseases of the Chinese Academy of Medical Sciences: Construction and Application of Big Data Database for Specialised Blood System Diseases” that we participated in its construction, was named as a typical digital health case in the “Development of Big Data Applications in Health Care”.

During the Reporting Period, we undertook the construction of the “Data Platform for Clinical Trial Institution Evaluation” jointly promoted by the National Medical Products Administration (NMPA), and Chinese Academy of Medical Sciences & Peking Union Medical College. This is the fourth national platform we have built. The platform will perform full process evaluations of clinical trial organizations, and realize data collection and online configuration and management of evaluation models, provide effective quality control and analysis tools for evaluation work, and facilitate efficient analysis and decision-making.

In the field of public health, our solution can help regulators assess basic medical insurance burden and risk trends of the regional population, in order to develop corresponding policies and measures and, at the same time, manage and allocate medical resources more effectively. During the Reporting Period, we won the bid for Overseas Outbreak Monitoring and Early Warning for Infectious Diseases project of Chinese Center for Disease Control and Prevention (China CDC), which will gradually improve its surveillance and early warning platform and system for overseas outbreak of infectious diseases. Through early identification of the spread of infectious diseases abroad and systematic analysis of infectious diseases overseas, China CDC will be able to prevent and control infectious diseases at earlier stages.

In addition to providing regional platform construction and public health solutions, with our AI-enabled analytical tools and cutting-edge simulation models, we also assisted in building cities’ “health brain” in the field of population health management. In an economically developed city in East China, we used artificial intelligence technology to enable efficient interoperability of healthcare data within the city, and meet the expectations of regulators and healthcare institutions for in-depth data utilisation in various scenarios including clinical research, diagnosis and treatment, early warning analysis and health management. In addition, during the Reporting Period, we also won the bid for the construction of regional healthcare profiling for local residents in Chaoyang District of Beijing, bridging residential medical data between hospitals in Chaoyang District to form an electronic health record for residents in Chaoyang District.

Life Sciences Solutions (“LSS”)

In the LSS segment, we currently provide analytics-driven intelligent clinical development, real-world evidence (RWE) based research, and digital commercialization solutions in respect of the full life-cycle of drugs or medical devices from clinical development to post-market commercialization to meet the diverse needs of our customers. Leveraging the disease insights empowered by AI and digital technology solutions, we help our partners in pharmaceutical, biotech, medical device and other clinical development processes to reduce the time and costs of drugs and medical devices development and improve the quality of clinical trials while achieving commercial success.

As a pioneer of innovative digital intelligence clinical trials in China, in view of the issues of low recruitment rate, poor compliance, slow progress of clinical trials and high cost of drug development in traditional clinical trials, we have independently developed an integrated digital intelligence service platform, which mainly includes digital collaboration platform and decentralized clinical trial platform (DCT), based on the core capabilities of YiduCore and the top tier hospitals and experts network accumulated in the BDPS segment under the guidance of patient-centered drug development. In 2020, the LSS segment published the “Blue Book on Decentralized Clinical Trials” in collaboration with experts from various industry parties and released the “Expert Consensus on Decentralized Clinical Trials” in 2022. During the Reporting Period, the BDPS segment undertook the construction of the “Data Platform for Clinical Trial Institution Evaluation” jointly promoted by the NMPA, Chinese Academy of Medical Sciences and Peking Union Medical College. The platform will perform full process evaluations of clinical trial organizations, and realize data collection and online configuration and management of evaluation models, provide effective quality control and analysis tools for evaluation work, and facilitate efficient analysis and decision-making. In addition, during the Reporting Period, the LSS segment provided a DCT digital solution for XIANNUOXIN[®] (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged)), an innovative anti-COVID-19 drug jointly developed by Simcere Pharmaceutical Group Limited, the Shanghai Institute of Materia Medica of Chinese Academy of Sciences, and Wuhan Institute of Virology of Chinese Academy of Sciences, which promoted the smooth development of the project and helped to accelerate the launch of the drug, and was awarded the title of “Best Partner”.

Our capabilities in generating high-quality real-world evidences to empower life science clients to manage and optimize the entire product life-cycle, from obtaining drug approval, peri-launch evidence support, post-marketing growth, to label extension, have all been validated. During the Reporting Period, we provided a real-world study service to a multinational pharmaceutical company (MNC) client on a product indicated for eosinophilic granulomatosis with polyangiitis, and evidence generated from the study facilitated the drug’s inclusion into China’s national medical insurance catalogue. Eosinophilic granulomatosis with polyangiitis is a rare disease and accelerating its approval for medical insurance will meet the clinical needs of patients with this rare disease in China. In November 2022, in collaboration with the research team of the LSS segment, Becton, Dickinson and Company released the “Research Report on Value Assessment and Practical Application of High-Value Medical Consumables” to promote the practices and application of value assessment framework and index system of high-value medical consumables in the two scenarios of health insurance and hospitals. In March 2023, the paper titled “Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in the ‘Boao Lecheng Pilot Zone’”, which was prepared by NMPA’s Hainan Key Laboratory of Real World Data Research and Evaluation in collaboration with the LSS segment, was published in the international journal “Cost Effectiveness and Resource Allocation”, the staff of the LSS segment is the first author of the paper.

Over the past years, the LSS segment maintained strong growth momentum, especially in the analytics-driven clinical development solutions. However, the prolonged COVID-19 pandemic delayed customer site implementation delivery, and resulted in a year-on-year decrease of revenue in this segment during the Reporting Period. As of 31 March 2023, the segment's revenue amounted to RMB252.9 million, representing a year-on-year decrease of 29.6%. Under the strategic focus, we focus on digital and intelligent technological innovation to continuously improve customer experience, channel innovation, and improvement of operating efficiency. With accumulated experience in focused disease research areas, especially for solid tumors, hematology, ophthalmology, immunology and cardiovascular, we have earned a good reputation in the life science industry. As of 31 March 2023, we have performed 255 clinical researches, including clinical trials sponsored by pharmaceutical companies and investigator-initiated trials (IIT). We have performed 204 prospective and retrospective real-world studies. Our Intelligent Site Management Organization (iSMO) services have covered 174 clinical trial facilities. The growing show cases enable us to continuously develop our competence and maintain a high quality of customer base. As of 31 March 2023, we have 167 active clients, of which 154 are core pharmaceutical, biotech and medical device corporate customers. During the Reporting Period, we achieved a 94.1% revenue retention rate for our top 10 clients in terms of revenue. Among our top 20 clients in terms of revenue, there are 6 MNC and 17 listed companies.

We actively seek new avenues for networking and business development with key opinion leaders and industry experts. For example, we hosted "Happy and Smart Study" live broadcast event to help industry participants and potential clients understand the latest breakthroughs in the industry and our core competence. As of 31 March 2023, we have organized a total of 18 live broadcast events, covering hot topics on ADC and CAR-T drug development, experience sharing of real-world studies contributing to regulatory approvals for drugs and devices, Causa Research DCT platform press conference, etc. We have also invited 86 industry leaders and clinical experts to share insights, and attracted more than 4,000 clinical researchers to participate in study and discussion.

We have a team of professionals with rich experience and cross-domain expertise. As of 31 March 2023, our employees of the LSS segment have an average of 8 years of relevant experience with expertise spanning clinical research, data science, epidemiology, biostatistics, medical informatics, AI and others. We remain committed to create processes in improving the operating efficiency not only by developing a high-caliber talent pool but also by optimizing client value. In addition, the LSS segment has established intelligent full-process management tools for clinical trial project and relatively higher quality control standards. Our intelligent quality management system covers all stages of a project from clinical design and project planning, to quality control, and to retrospective and prospective real-world studies. Meanwhile, we also established SOPs for clinical research of CAR-T offerings to ensure high-quality service. Like algorithms, digitized SOPs are timely iterated based on the feedback from real cases.

Health Management Platform and Solutions (“HMPS”)

In the HMPS segment, we provide one-stop health management solutions, including health management solutions, chronic disease management services, commercial health insurance and Hui Min Bao (惠民保), a city-level supplementary insurance to the existing national social medical insurance, to provide multi-level healthcare solutions for cities with tens of millions of populations. During the Reporting Period, the revenue of our HMPS segment amounted to RMB329.9 million, representing a year-on-year decrease of 22.4%, mainly due to the adjustment of our product mix.

In order to achieve our mission “to make value-based precision healthcare accessible to everyone”, we provide innovative insurance technologies and solutions to insurers, brokers and relevant regulators and policymakers in this sector. Leveraging our medical knowledge and insights accumulated through YiduCore, we continuously improve medical actuarial models, intelligent risk control models, and disease prediction models, and strengthen the construction of five core capabilities including patient analysis and risk assessment, customised product development, hierarchical classification of large-scale population, health intervention and intelligent customer service, intelligent underwriting and quick claim settlement. Our solutions aim to empower our customers with technology to design and develop innovative insurance products, enabling faster and more accurate insurance underwriting and expediting claim processing.

During the Reporting Period, we continued to increase the market penetration of the Hui Min Bao business. As of 31 March 2023, we won the bid in and served 4 provinces and 12 cities, including Jiangsu Province, Fujian Province, Anhui Province, Shaanxi Province, Beijing, Shenzhen, Tianjin, Ningbo, etc. We focus on core cities to expand the regional network, over 90% of our users are in the China’s top 15 provincial-level administrative regions in terms of GDP in 2022. We have assisted three of the four municipalities directly under the central government in China to launch the Hui Min Bao products, including Tianjin, Beijing and Chongqing. During the Reporting Period, as the leader of a consortium, we won the bid for the third party platform project of Shenzhen Hui Min Bao (深圳惠民保) and provided main operating services, which effectively ensured the implementation and stable operation of the project and further solidified the leadership position of our Hui Min Bao business in China’s core urban cities.

With the support of healthcare intelligent technology and rich experience in scenario operation, we have been able to provide one-stop operation solutions for Hui Min Bao in provinces and cities with tens of millions of populations such as Beijing and Jiangsu Province. We served as the main operation platform for Beijing Pu Hui Jian Kang Bao (北京普惠健康保) and Jiangsu Yi Hui Bao No. 1 (江蘇醫惠保1號) for two consecutive years. The total number of the insured for 2023 Beijing Pu Hui Jian Kang Bao amounted to 3.50 million, representing an increase of approximately 14% over the previous year. The total number of the insured for 2023 Jiangsu Yi Hui Bao No. 1 amounted to 5.08 million, representing an increase of approximately 58% over the previous year.

Leveraging algorithm models and AI technologies, we assisted 2022 Beijing Pu Hui Jian Kang Bao to launch quick claim services. The vast majority of the insured are not required to provide claim materials such as medical bills, but are actively reached and provided compensation by receiving text messages and phone calls and other means. At present, more than 85% of the beneficiaries obtained claims through the quick claim service, which has significantly compressed the claim settlement time and reduced the financial burden of the insured. 2023 Beijing Pu Hui Jian Kang Bao further upgraded its products with the number of health management services increased from 25 in the previous year to 42, and for the first time, new citizens who are not covered by Beijing basic medical insurance are also eligible, and those who have Beijing household registration or Beijing residence permits and participated the basic medical insurance in other cities can participate in the insurance, extending the inclusiveness of Hui Min Bao to more people and reducing the burden of medical expenses on residents.

The high-quality user base and extensive user operation enable us to increase the user traffic from Hui Min Bao and enhanced our brand awareness among the general population. Our technology-empowered Hui Min Bao services have been widely recognized by the market. At the 2022 Healthy China Innovation Practice Case Collection and Summary Conference (2022 健康中國創新實踐案例徵集總結大會) organized by People's Daily Online, the Hui Min Bao project we submitted was named the "2022 Healthy China Innovation Practice Typical Case (2022 健康中國創新實踐典型案例)". Our operation in Beijing Pu Hui Jian Kang Bao and Jiangsu Yi Hui Bao No. 1 were awarded "Comprehensive Excellent Case", and "Special Excellent Case", respectively.

We also deliver AI one-stop analytics-driven solutions by leveraging technology capabilities and medical knowledge accumulated by YiduCore, and offer integrated and personalized digital therapeutics that integrates traditional treatment with out-of-hospital care and lifestyle interventions. During the Reporting Period, the diabetes digital therapeutics product based on the diabetes digital therapeutics independently developed by us has been approved by the U.S. Food and Drug Administration ("FDA"). In addition, based on the independently-developed diabetes digital therapeutics, the diabetes digital therapeutics product for China developed by us has been approved by Hainan Medical Products Administration of China and received the Medical Device Registration Certificate of the People's Republic of China. With the maturity of the solution, we plan to expand our regional coverage to benefit more people.

As of 31 March 2023, the number of active users who have completed at least one transaction on our health management platform reached 20 million.

Business outlook

To achieve our mission to "make value-based precision healthcare accessible to everyone" and further solidify our leadership in the healthcare intelligence industry, we will continue to (i) focus on the state-of-art technology development in the field of artificial intelligence and continue to explore and independently innovate in this vertical area of the healthcare industry, (ii) strengthen investment in YiduCore, to further enhance the output efficiency of product upgrade and iteration, (iii) deepen and broaden our knowledge, research and use-cases in each key disease areas, (iv) improve operation efficiency in customer value delivery, (v) improve

synergy among the business sectors to increase penetration and repurchase rate of high-quality customers, (vi) explore opportunities in international markets, and (vii) enrich our ecosystem through strategic partnerships, investments and acquisitions.

In respect of Big Data Platform and Solutions, we will continue to strengthen our “two-pronged” strategy. Horizontally, we will continue to (i) expand our network of hospitals and urban regions, (ii) enrich the use-case scenarios of existing customers, and continuously enlarge our customer bases by product innovation, and (iii) continuously enhance the functionality, reliability and usability of our products in combination with state-of-art technology development. Vertically, we will continue to deepen and optimize our research within each key disease area by enabling multi-site research to be carried out based on disease dimensions and hospital networks.

In respect of Life Sciences Solutions, with the constant development of AI technology, and the concept of “patient-centered” research and development being more integrated throughout full life-cycle of the medicine research and development, we will continue to accelerate the generation of research-grade evidence based on YiduCore to drive the development of our one-stop solutions from analytics-driven clinical development to post-market commercialization. Our focus will remain on the following areas: (i) the upgrade and iteration of our integrated digital intelligence-based service platform and operational efficiency improvement of such service platform, (ii) generation and application of RWE, (iii) key disease areas we excel at in clinical development, and (iv) preservation and enlargement of our customer base.

In respect of Health Management Platform and Solutions, we will continue to utilize our disease insights, knowledge and expert network to provide effective health management solutions to benefit more people with “patient-centered, outcome-oriented” care. We will continue to (i) increase the number of active users on our platform from diversified channels, (ii) expand our health management product offerings to meet the multi-level mass medical needs, and (iii) enrich user experience to solidify brand loyalty.

We are well positioned to serve as a leading player in the rapidly evolving healthcare intelligence industry. In the future, we will continue to introduce innovative AI-driven applications and solutions to capture the massive market opportunities in China and beyond, to enable stakeholders in the ecosystem to derive more value from our intelligent “medical brain”.

MANAGEMENT DISCUSSION AND ANALYSIS

Revenues

Our revenues decreased by 35.0% from RMB1,237.2 million for the fiscal year ended 31 March 2022 to RMB804.7 million for the fiscal year ended 31 March 2023. The decrease was primarily attributable to the decreases in revenue from Big Data Platform and Solutions and Life Science Solutions segments.

Big Data Platform and Solutions. Revenue from Big Data Platform and Solutions decreased by 50.1% from RMB444.9 million for the fiscal year ended 31 March 2022 to RMB221.9 million for the fiscal year ended 31 March 2023, primarily due to the delay in the clients' tendering processes, on-site implementation, and clients' acceptance resulting from the prolonged impact of the COVID-19 pandemic.

Life Sciences Solutions. Revenue from Life Sciences Solutions decreased by 29.6% from RMB359.4 million for the fiscal year ended 31 March 2022 to RMB252.9 million for the fiscal year ended 31 March 2023, primarily due to the delay in the clients' on-site implementation and delivery resulting from the prolonged impact of the COVID-19 pandemic.

Health Management Platform and Solutions. Revenue from Health Management Platform and Solutions decreased by 22.4% from RMB424.9 million for the fiscal year ended 31 March 2022 to RMB329.9 million for the fiscal year ended 31 March 2023, primarily due to the adjustment of our product mix.

Others. Other revenue decreased by 100% from RMB8.0 million for the fiscal year ended 31 March 2022 to nil for the fiscal year ended 31 March 2023.

Cost of Sales and Services

Our cost of sales and services decreased by 36.7% from RMB837.8 million for the fiscal year ended 31 March 2022 to RMB530.2 million for the fiscal year ended 31 March 2023. Share-based compensation expenses included in cost of sales and services were RMB13.2 million and RMB8.0 million for the fiscal years ended 31 March 2022 and 2023 respectively. The decrease was caused by cost saving in the Big Data Platform and Solutions, Life Science Solutions, Health Management Platform and Solutions segments for the fiscal year 2023.

Big Data Platform and Solutions. Cost of sales and services from Big Data Platform and Solutions segment decreased by 50.1% from RMB252.3 million for the fiscal year ended 31 March 2022 to RMB126.0 million for the fiscal year ended 31 March 2023, primarily due to (i) the decreased cost of software and hardware as well as outsourcing service fee from RMB169.5 million to RMB65.4 million; (ii) decrease in employee benefits and expenses of employees engaging in the Big Data Platform and Solutions business from RMB77.4 million to RMB59.3 million, which included share-based compensation expenses of RMB7.0 million and RMB3.8 million in the respective years.

Life Sciences Solutions. Cost of sales and services from Life Sciences Solutions decreased by 22.9% from RMB270.8 million for the fiscal year ended 31 March 2022 to RMB208.7 million for the fiscal year ended 31 March 2023, primarily due to the decreases in (i) outsourcing service fee from RMB160.7 million to RMB113.3 million, and (ii) employee benefits and expenses of employees engaging in the Life Sciences Solutions business from RMB100.4 million to RMB88.4 million, which included share-based compensation expenses of RMB2.7 million and RMB2.1 million in the respective years.

Health Management Platform and Solutions. Cost of sales and services from the Health Management Platform and Solutions segment decreased by 36.4% from RMB307.3 million for the fiscal year ended 31 March 2022 to RMB195.5 million for the fiscal year ended 31 March 2023, primarily due to decrease in cost of pharmaceutical products and services from RMB275.4 million to RMB171.5 million.

Others. Other cost of sales and services decreased by 100% from RMB7.5 million for the fiscal year ended 31 March 2022 to nil for the fiscal year ended 31 March 2023.

Gross profit and gross margin

As a result of the foregoing, our overall gross profit for the fiscal years ended 31 March 2022 and 2023 were RMB399.4 million and RMB274.5 million respectively, and our overall gross margin was 32.3% and 34.1% respectively, which maintained steady growth despite the tough external environment.

Big Data Platform and Solutions. Our gross margin in Big Data Platform and Solutions maintained relatively stable at 43.2% for the fiscal year ended 31 March 2023 compared with 43.3% for the fiscal year ended 31 March 2022.

Life Sciences Solutions. Our gross margin in Life Sciences Solutions decreased from 24.7% for the fiscal year ended 31 March 2022 to 17.5% for the fiscal year ended 31 March 2023, primarily due to the decrease of cost at a slower rate as the Company retained the delivery team for foreseeable business opportunities despite the decrease in revenue generated as the result of prolonged impact of COVID-19 pandemic for the fiscal year ended 31 March 2023.

Health Management Platform and Solutions. Our gross margin in Health Management Platform and Solutions increased from 27.7% for the fiscal year ended 31 March 2022 to 40.7% for the fiscal year ended 31 March 2023, primarily due to the change of our product mix.

Selling and marketing expenses

Our selling and marketing expenses decreased by 34.4% from RMB413.9 million for the fiscal year ended 31 March 2022 to RMB271.6 million for the fiscal year ended 31 March 2023, primarily attributable to (i) employee benefits and expenses of employees engaging in selling and marketing function decreased from RMB234.7 million to RMB165.0 million, which included share-based compensation of RMB27.9 million and RMB17.1 million in the respective years; (ii) business development, promotion and advertising expenses for the Group's marketing activities and insurance services decreased from RMB105.9 million to RMB34.3 million.

Selling and marketing expenses as a percentage of revenue maintained relatively stable at 33.8% for the fiscal year ended 31 March 2023 compared with 33.5% for the fiscal year ended 31 March 2022.

Administrative expenses

Our administrative expenses decreased by 31.2% from RMB337.0 million for the fiscal year ended 31 March 2022 to RMB232.0 million for the fiscal year ended 31 March 2023, primarily attributable to decreases in (i) employee benefits and expenses of employees engaging in administrative function from RMB249.3 million to RMB182.5 million, which included share-based compensation of RMB99.5 million and RMB47.6 million in the respective years; and (ii) consulting fee from RMB37.4 million to RMB2.6 million.

As a percentage of revenue, administrative expenses maintained relatively stable at 28.8% for the fiscal year ended 31 March 2023, compared with 27.2% for the fiscal year ended 31 March 2022.

Research and development expenses

Our research and development expenses decreased by 7.1% from RMB368.7 million for the fiscal year ended 31 March 2022 to RMB342.5 million for the fiscal year ended 31 March 2023. The decrease in research and development expenses was primarily due to (i) the decrease in employee benefit and expenses for employees engaging in research and development function from RMB292.4 million to RMB259.7 million, including the decrease in share-based compensation from RMB42.2 million to RMB26.3 million in the respective years; and (ii) the increase in technical and consulting services fees from RMB32.9 million to RMB45.5 million.

As the Company focused on maintaining its technological leadership and continuously increasing research and development investment, as a percentage of revenue, research and development expenses increased from 29.8% for the fiscal year ended 31 March 2022 to 42.6% for the fiscal year ended 31 March 2023.

Operating loss

As a result of the foregoing, our operating loss decreased by 17.9% from RMB767.4 million for the fiscal year ended 31 March 2022 to RMB630.0 million for the fiscal year ended 31 March 2023.

Taxation

Income tax (credit)/expense of the Group increased from RMB(0.5) million for the fiscal year ended 31 March 2022 to RMB3.4 million for the fiscal year ended 31 March 2023.

Loss for the year

As a result of the foregoing, our loss for the year decreased by 17.5% from RMB766.4 million for the fiscal year ended 31 March 2022 to RMB632.4 million for the fiscal year ended 31 March 2023.

Non-IFRS Measure — Adjusted Net Loss

To supplement our consolidated financial statements which are presented in accordance with International Financial Reporting Standards (“IFRS”), we also use adjusted net loss (as defined below) as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that the presentation of this non-IFRS measure facilitates comparisons of operating performance from period to period and company to company by eliminating potential impact of items that our management does not consider to be indicative of our operating performance such as certain non-cash items and certain impact of investment transactions. We believe that this measure provides useful data to investors in understanding and evaluating the Group’s consolidated results of operations in the same manner as they help our management. However, the use of non-IFRS measure has limitations as an analytical tool, and you should not consider them in isolation from, or as a substitute for analysis of, our results of operations or financial conditions as reported under IFRS. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies.

We define “adjusted net loss” as loss for the year and adding back (i) share-based compensation expenses; (ii) net foreign exchange losses.

For the fiscal years ended 31 March 2022 and 2023, our adjusted net losses were RMB577.0 million and RMB448.7 million respectively.

The table below sets forth the reconciliation of our non-IFRS financial measure for the fiscal years ended 31 March 2022 and 2023 to the closest indicator prepared in accordance with IFRS.

	Years ended 31 March	
	2023	2022
	(RMB'000)	(RMB'000)
Loss for the year	(632,361)	(766,360)
Add:		
Share-based compensation expenses ⁽¹⁾	99,035	182,839
Net foreign exchange losses ⁽²⁾	84,614	6,558
Non-IFRS adjusted net loss	(448,712)	(576,963)
Non-IFRS adjusted net loss margin (%)⁽³⁾	(55.8)	(46.6)

(1) Share-based compensation expenses relate to the share awards we offered to our employees, directors and consultants under the Share Incentive Plans, which are primarily non-cash in nature and commonly not included in similar non-IFRS measures adopted by other companies in our industry.

(2) Net foreign exchange losses are primarily non-cash in nature and commonly not included in similar non-IFRS measures adopted by other companies in our industry.

(3) Represents non-IFRS adjusted net loss divided by the total revenue for the periods indicated.

Liquidity and capital resource

During the fiscal year ended 31 March 2023, we had funded our cash requirements principally by capital contribution from shareholders and financing through issuance and sales of convertible redeemable preferred shares in private placement transactions and proceeds from initial public offering. We had cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits of RMB3,732.1 million and RMB3,522.0 million as of 31 March 2022 and 2023 respectively.

Significant investments

During the fiscal year ended 31 March 2023, Marvelous Panda Inc., a wholly-owned subsidiary of the Company, entered into a subscription agreement for the fund YD Capital I L.P. (the “**Fund**”) with the general partner and became a limited partner of the Fund by making a cash contribution of US\$40.0 million to the Fund, representing 40% of the fund commitment. During the fiscal year ended 31 March 2023, the cash equivalent to US\$557,748.0 was paid by the Group. The purpose of the Fund is primarily to (i) make venture capital investments in the healthcare sector, (ii) manage, supervise and dispose of such investments, and (iii) engage in such other activities incidental or ancillary thereto as the general partner deems necessary, appropriate or advisable.

Material acquisitions and disposals

During the fiscal year ended 31 March 2023, the Company has sold 20% of the issued share capital of EVYD Technology Limited (“**EVYD BVI**”) at a transaction consideration of US\$55.0 million. Upon the completion of the transaction, the Company indirectly hold an aggregate of 70.1% of the issued shares of EVYD BVI, and therefore remains to be the controlling shareholder of EVYD BVI after the disposal. The disposal had no impact on the Group’s income statement. As for the Group’s balance sheet, the Group recorded from the disposal an increase in the Group’s “Other Reserves” of an amount of RMB316.6 million, and an increase in the Group’s “Non-controlling Interests” in an amount of RMB59.9 million.

Pledge of assets

As at 31 March 2023, the Group had no material pledge of assets.

Future plans for material investments or capital asset

As at 31 March 2023, the Group did not have detailed future plans for material investments or capital assets.

Foreign exchange exposure

During the fiscal year ended 31 March 2023, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of our Company, the subsidiaries and the consolidated affiliated entities that operate in the PRC, and the subsidiary operate in the Brunei are U.S. dollar, Renminbi and Brunei dollar, respectively. For the fiscal year ended 31 March 2023, we had currency exchange gains of RMB300.1 million and net foreign exchange losses of RMB84.6 million, compared to a currency exchange loss of RMB141.8 million and a net foreign exchange loss of RMB6.6 million for the fiscal year ended 31 March 2022. We did not hedge against any fluctuation in foreign currency during the fiscal years ended 31 March 2022 and 2023.

Contingent liabilities

As at 31 March 2023, we did not have any material contingent liabilities (as at 31 March 2022: nil).

Capital commitment

As at 31 March 2023, capital commitment of the Group was RMB2.3 million, mainly renovation expenses (as at 31 March 2022: RMB2.3 million, mainly for the purchase of equipment).

Investment commitment

As at 31 March 2023, investment commitment of the Group was RMB284.0 million (as at 31 March 2022: RMB1.9 million), mainly for the outstanding contribution from Marvelous Panda Inc., a wholly-owned subsidiary of the Company, to the Fund YD Capital I L.P.

Employees and remuneration

As at 31 March 2023, the Group had a total of 1,020 employees, with 537 employees based in Beijing, 133 employees in Shanghai and 350 employees in other offices in China and overseas. The table below sets forth the total number of employees by function as at 31 March 2023:

Function	Number of employees
Product Development and Technology	411
Medical Function	354
Sales and Marketing	119
General and Administrative	136
Total	1,020

Our people are our most valued assets. We are able to continue to attract the best talents across multiple domains due to our influence in the industry and professionalism. As at 31 March 2023, about 53.5% of our employees have medical background and experiences, and about 30.1% have AI and technology experiences and background. The total remuneration cost incurred by the Group for the fiscal year ended 31 March 2023 was RMB777.7 million, as compared to RMB982.5 million for the fiscal year ended 31 March 2022. The Company has also adopted a post-IPO share award scheme and a post-IPO share option scheme.

Subsequent Event

As at the date of this announcement, the Group has no significant events occurred after the Reporting Period which require additional disclosures or adjustments.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability, and the shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 15 January 2021 (the “**Listing Date**”).

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

Compliance with the Code on Corporate Governance Practices

During the Reporting Period, the Company has complied with the Corporate Governance Code (the “**Corporate Governance Code**”) set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), save for the following deviations.

Code provision F.1.1 of the Corporate Governance Code provides that the issuer should have a policy on payment of dividends and should disclose it in the annual report. As the Company intends to retain its available funds and earnings to fund the development and growth of our business, the performance of which will continue to be impacted by the relevant industry’s and economic outlook in the foreseeable future, the Board is of the opinion that it is not appropriate to adopt a dividend policy at this stage. The Board will review the Company’s status periodically and consider to adopt a dividend policy if and when appropriate.

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix 10 of the Listing Rules as its own code of conduct regarding directors’ securities transactions.

Specific enquiry has been made of all the Directors and the relevant employees and they have confirmed that they have complied with the Model Code during the Reporting Period.

Audit committee

The Group has established the Audit Committee comprising three members, being Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi, with Ms. Pan Rongrong (being the Company's independent non-executive Director with the appropriate professional qualifications) as chair of the Audit Committee.

The Audit Committee has reviewed the audited consolidated financial statements of the Group for the fiscal year ended 31 March 2023 and has met with the independent auditor, PricewaterhouseCoopers (the “**Auditor**”). The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

Auditor's scope of work

The figures in respect of the Group's consolidated statement of comprehensive income, consolidated balance sheet and the related notes thereto for the fiscal year ended 31 March 2023 contained in this announcement have been agreed by the Auditor, to the amounts set out in the audited consolidated financial statements of the Group for the fiscal year ended 31 March 2023. The work performed by the Auditor in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the Auditor on this announcement.

OTHER INFORMATION

Purchase, sale or redemption of the Company's listed securities

During the Reporting Period, neither the Company nor any of its subsidiaries or consolidated affiliated entities purchased, sold or redeemed any of the Company's listed securities.

Material litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period and up to the date of this announcement.

Use of proceeds from global offering

On 15 January 2021, the shares of the Company were listed on the Main Board of the Stock Exchange. The net proceeds from the global offering (following full exercise of the Over-allotment Option, as defined in the prospectus of the Company dated 31 December 2020 (the “**Prospectus**”)) were approximately RMB3,825 million (the “**Net Proceeds**”), which are intended to be applied in the manner set out in the Prospectus. There was no change in the intended use of proceeds as previously disclosed.

Set out below is the status of use of proceeds from the global offering as at 31 March 2023 and 2022.

Purpose	% of use of proceeds	Net proceeds (RMB million)	Amount		Unutilised amount as at 31 March 2023 (RMB million)	Unutilised amount as at 31 March 2022 (RMB million)	Expected time of full utilisation
			Unutilised amount as at 31 March 2023	used in the fiscal year ended 31 March 2023			
Strengthen our core capabilities	35%	1,339	1,339	254	1,085	31 March 2025	
Further our business expansion	35%	1,339	1,339	725	614	31 March 2025	
Further enrich our ecosystem through strategic partnerships, investments and acquisitions	20%	765	765	17	748	31 March 2024	
Working capital and general corporate purposes	10%	382	382	119	263	31 March 2025	

The above Net Proceeds were translated with spot rates on the Listing Date, while the cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits as of 31 March 2023 were translated with spot rates on its balance sheet date.

As of 31 March 2023, the Company had utilised RMB1,115 million of the Net Proceeds.

Dividend

The Board does not recommend the distribution of a final dividend for the fiscal year ended 31 March 2023.

Closure of register of members

The Company's annual general meeting (the "AGM") will be held on 25 August 2023, Friday. The register of members of the Company will be closed for the purpose of determining the identity of members who are entitled to attend the AGM from 22 August 2023, Tuesday to 25 August 2023, Friday, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend the AGM, all duly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration, no later than 4:30 p.m. on 21 August 2023, Monday.

Consolidated Statement of Comprehensive Income

	Years ended 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Revenue from contracts with customers	804,700	1,237,200
Cost of sales and services	<u>(530,170)</u>	<u>(837,755)</u>
Gross profit	<u>274,530</u>	<u>399,445</u>
Selling and marketing expenses	(271,637)	(413,934)
Administrative expenses	(231,989)	(337,032)
Research and development expenses	(342,519)	(368,659)
Net impairment losses on financial assets and contract assets	(61,953)	(48,798)
Impairment of non-financial assets	(3,287)	(12,938)
Other income	97,349	38,659
Other losses — net	<u>(90,543)</u>	<u>(24,141)</u>
Operating loss	<u>(630,049)</u>	<u>(767,398)</u>
Finance income	7,998	4,972
Finance costs	<u>(2,611)</u>	<u>(4,213)</u>
Finance income — net	<u>5,387</u>	<u>759</u>
Share of losses from investments in associates	<u>(4,277)</u>	<u>(207)</u>
Loss before income tax	<u>(628,939)</u>	<u>(766,846)</u>
Income tax (expense)/credit	<u>(3,422)</u>	<u>486</u>
Loss for the year	<u>(632,361)</u>	<u>(766,360)</u>
Loss is attributable to:		
Owners of the Company	(627,966)	(762,318)
Non-controlling interests	<u>(4,395)</u>	<u>(4,042)</u>
	<u>(632,361)</u>	<u>(766,360)</u>

	Years ended 31 March	
	2023	2022
	RMB'000	RMB'000
Other comprehensive income/(loss)		
<i>Item that will not be reclassified to profit or loss:</i>		
Currency translation differences	489,998	(203,439)
<i>Item that will be reclassified to profit or loss:</i>		
Currency translation differences	<u>(189,942)</u>	<u>61,632</u>
Other comprehensive income/(loss) for the year, net of tax	<u>300,056</u>	<u>(141,807)</u>
Total comprehensive loss for the year	<u>(332,305)</u>	<u>(908,167)</u>
Total comprehensive loss for the year is attributable to:		
Owners of the Company	(328,520)	(903,215)
Non-controlling interests	<u>(3,785)</u>	<u>(4,952)</u>
	<u>(332,305)</u>	<u>(908,167)</u>
Loss per share, basic and diluted (RMB)	<u>(0.63)</u>	<u>(0.80)</u>

Consolidated Balance Sheet

	As at 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Assets		
Non-current assets		
Property, plant and equipment	72,584	59,344
Right-of-use assets	11,249	43,381
Intangible assets	39,531	35,249
Deferred income tax assets	345	1,238
Investments accounted for using the equity method	5,282	9,915
Financial assets at fair value through profit or loss	23,115	16,461
Pledged bank deposits	1,262	—
Long-term investments measured at amortized cost	240,510	—
Restricted bank balance and deposits	6,208	5,024
	<hr/>	<hr/>
Total non-current assets	400,086	170,612
Current assets		
Inventories	3,733	5,736
Contract assets	123,706	158,749
Trade receivables	474,498	513,244
Other financial assets at amortised cost	81,843	70,656
Financial assets at fair value through profit or loss	230,093	36,927
Pledged bank deposits	2,077	—
Term deposits	2,339,699	318,595
Cash and cash equivalents	1,172,793	3,408,505
Other current assets	82,980	39,786
	<hr/>	<hr/>
Total current assets	4,511,422	4,552,198
	<hr/>	<hr/>
Total assets	4,911,508	4,722,810

	As at 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Equity		
Equity attributable to owners of the Company		
Share capital	131	124
Treasury shares	(1)	(1)
Other reserves	12,948,250	12,227,727
Accumulated deficits	<u>(8,866,016)</u>	<u>(8,238,050)</u>
	4,082,364	3,989,800
Non-controlling interests	<u>73,787</u>	<u>17,666</u>
Total equity	<u>4,156,151</u>	<u>4,007,466</u>
Liabilities		
Non-current liabilities		
Lease liabilities	4,590	25,987
Deferred income	<u>79,761</u>	<u>77,774</u>
Total non-current liabilities	<u>84,351</u>	<u>103,761</u>
Current liabilities		
Trade and other payables	386,863	329,506
Deferred income	4,208	10,500
Salary and welfare payable	200,615	205,656
Contract liabilities	56,943	33,256
Current income tax liabilities	1,539	245
Lease liabilities	9,538	26,178
Provisions	<u>11,300</u>	<u>6,242</u>
Total current liabilities	<u>671,006</u>	<u>611,583</u>
Total liabilities	<u>755,357</u>	<u>715,344</u>
Total equity and total liabilities	<u>4,911,508</u>	<u>4,722,810</u>

NOTES TO FINANCIAL STATEMENTS

1 General information

Yidu Tech Inc. (the “**Company**”) was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability under the Companies Act of the Cayman Islands (Cap. 22, Law 3 of 1961 as consolidated and revised). The address of the Company is at Suite #4–210, Governors Square, 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the “**Group**”) are primarily engaged in the provision of the following services: i) big data platform and solutions, ii) life sciences solutions, iii) health management platform and solutions, and iv) others in the People’s Republic of China (“**PRC**”).

These financial statements are presented in Renminbi (“**RMB**”), unless otherwise stated.

2 Summary of significant accounting policies

The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Basis of preparation

(i) Compliance with IFRS

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“**IFRS**”) as issued by International Accounting Standards Board (“**IASB**”).

The preparation of consolidated financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 4 of consolidated financial statements.

(ii) Historical cost convention

The consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss.

(iii) New and amended standards adopted by the Group

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing 1 April 2022:

- IFRS 17 — Insurance Contracts
- Amendments to IAS 1 and IFRS Practice Statement 2 — Disclosure of Accounting Policies
- Amendments to IAS 8 — Definition of Accounting Estimates
- Amendments to IAS 12 — Deferred Tax related to Assets and Liabilities from a Single Transaction
- Amendments to IAS 1 — Classification of Liabilities as Current or Non-current
- Annual Improvements to IFRS Standards 2018–2021

The amendments listed above did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

(iv) New standards and interpretations not yet adopted

The Group has not early applied the following new and amendments to IFRS that have been issued but are not yet effective:

	Effective for annual periods beginning on or after
Amendment to IFRS 16— Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to IAS 1— Non-current Liabilities with Covenants	1 January 2024

The directors of the Company anticipate that the application of the above new standard, amendments and annual improvements will have no material impact on the Group's consolidated financial statements in the foreseeable future.

3 Segment information

Disaggregation of revenue from contracts with customers

The Group's business activities, for which discrete financial statements are available, are regularly reviewed and evaluated by the Chief Operating Decision Maker. As a result of this evaluation, the Group determined that it has operating segments as follows:

- Big data platform and solutions
- Life sciences solutions
- Health management platform and solutions
- Others

	Year ended 31 March 2023				
	Big data platform and solutions <i>RMB'000</i>	Life sciences solutions <i>RMB'000</i>	Health management platform and solutions <i>RMB'000</i>	Others <i>RMB'000</i>	Total <i>RMB'000</i>
Revenue from contracts with customers	221,863	252,884	329,953	—	804,700
Cost of sales and services	<u>(125,997)</u>	<u>(208,647)</u>	<u>(195,526)</u>	—	<u>(530,170)</u>
Gross profit	<u>95,866</u>	<u>44,237</u>	<u>134,427</u>	—	<u>274,530</u>

	Year ended 31 March 2022				
	Big data platform and solutions <i>RMB'000</i>	Life sciences solutions <i>RMB'000</i>	Health management platform and solutions <i>RMB'000</i>	Others <i>RMB'000</i>	Total <i>RMB'000</i>
Revenue from contracts with customers	444,891	359,375	424,941	7,993	1,237,200
Cost of sales and services	<u>(252,284)</u>	<u>(270,757)</u>	<u>(307,257)</u>	<u>(7,457)</u>	<u>(837,755)</u>
Gross profit	<u>192,607</u>	<u>88,618</u>	<u>117,684</u>	<u>536</u>	<u>399,445</u>

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC. For the years ended 31 March 2023 and 2022, the Group earns approximately 77% and 23%, 81% and 19% of total revenue from external customers located in the PRC and other countries, respectively. As at 31 March 2023 and 2022, majority of the non-current assets of the Group were located in the PRC and Cayman Islands.

	Years ended 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Segment revenue		
— recognised over time	386,437	520,324
— recognised at a point in time	418,263	716,876
	<u>804,700</u>	<u>1,237,200</u>
Segment revenue		
— gross	687,626	1,130,716
— net	117,074	106,484
	<u>804,700</u>	<u>1,237,200</u>

4 Expenses by nature

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are further analysed as follows:

	Years ended 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Employee benefits expenses	777,702	982,500
Outsourcing services fee	184,059	225,955
Cost of sales	166,152	388,668
Consulting and other professional fee	80,378	92,689
Travelling, entertainment and general office expenses	63,520	105,873
Promotion and advertising expenses	34,349	77,667
Depreciation of property, plant and equipment	24,033	21,529
Depreciation of right-of-use assets	15,063	20,016
Labour dispatching	11,958	21,725
Amortization of intangible assets	7,255	5,393
Auditors' remuneration	5,939	4,918
— Auditor of the Company	3,900	3,900
Taxes and surcharges	4,993	7,423
Other expenses	914	3,024
	<hr/>	<hr/>
Total cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses	<u>1,376,315</u>	<u>1,957,380</u>

5 Income tax expense/(credit)

	Years ended 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Current tax	2,529	—
Deferred income tax expense/(credit)	893	(486)
	<hr/>	<hr/>
Income tax expense/(credit)	<u>3,422</u>	<u>(486)</u>

6 Loss per share

Basic loss per share for the years ended 31 March 2023 and 2022 are calculated by dividing the loss attributable to the Company's owners by the weighted average number of ordinary shares in issue during the years.

The calculation of loss per share is based on the following:

	Years ended 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Loss attributable to owners of the Company	(627,966)	(762,318)
Weighted average number of ordinary shares in issue (<i>'000</i>)	995,204	957,776
Basic loss per share (<i>RMB yuan</i>)	<u>(0.63)</u>	<u>(0.80)</u>

7 Trade receivables

	As at 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
Trade receivables from contracts with customers		
— Third parties	581,506	597,186
— Related parties	—	1,787
Less: allowance for impairment of trade receivables	(107,008)	(85,729)
	<u>474,498</u>	<u>513,244</u>

(a) The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 180 days. The aging analysis of the trade receivables based on invoice date is as follows:

	As at 31 March	
	2023	2022
	RMB'000	RMB'000
— Up to 3 months	239,847	376,413
— 3 to 6 months	17,520	26,118
— 6 months to 1 year	93,067	87,308
— 1–2 years	178,274	45,746
— Over 2 years	52,798	63,388
	581,506	598,973
Less: allowance for impairment of trade receivables	(107,008)	(85,729)
Total	474,498	513,244

(b) *Fair values of trade receivables*

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

8 Trade and other payables

	As at 31 March	
	2023	2022
	RMB'000	RMB'000
Trade payables	160,426	210,604
Tax payables	10,172	12,368
Other payables:		
— Payables for consulting and other service fee	45,266	36,209
— Insurance premium collection payables	130,673	24,680
— Payables for repurchase of options	10,747	9,928
— Accrual for marketing and sales promotion expenses	6,469	8,228
— Payables for purchase of fixed assets	1,953	9,015
— Reimbursement payable to employees	7,370	7,182
— Payables for leasehold improvement	5,698	870
— Amounts due to related parties	—	66
— Payables for investment in venture capital fund	—	1,904
— Others	8,089	8,452
	386,863	329,506

- (i) The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.
- (ii) Aging analysis of the trade payables based on invoice date at the end of each reporting period are as follows:

	As at 31 March	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
— Up to 3 months	55,009	173,919
— 3 to 6 months	5,955	2,449
— 6 months to 1 year	28,441	23,450
— 1 to 2 years	69,306	9,383
— 2 to 3 years	1,317	1,403
— Over 3 years	398	—
	<u>160,426</u>	<u>210,604</u>

9 Dividend

No dividend has been paid or declared by the Company or the companies now comprising the Group during the years ended 31 March 2023 and 2022.

PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This annual results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.yidutechgroup.com). The annual report of the Group for the fiscal year ended 31 March 2023 will be dispatched to the Company's shareholders and made available for review on the same websites in due course.

By order of the Board
Yidu Tech Inc.
Gong Yingying
Executive Director and Chairlady

Hong Kong, 30 June 2023

As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Mr. Xu Jiming, Dr. Yan Jun and Ms. Feng Xiaoying; the non-executive Director is Mr. Zeng Ming; and the independent non-executive Directors are Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi.